2 1 century is the era of life science. Biotechnology has begun to play an increasingly important role in improving human health and living environment, and improving the output and quality of agriculture, animal husbandry and industry in important fields such as medical treatment, agriculture, environmental protection, light chemical industry and food. Biotechnology has become the focus of modern scientific research and development. In developed countries, biotechnology has become a new economic growth point, and its growth rate is about 25%-30%, which is about 8- 10 times of the average economic growth. Biomedicine in China 15 years growth 100 times.
In the field of biotechnology, China listed 10 major fields and 35 key technologies, and strived to cultivate more than 1000 large enterprises to realize the strategy of strengthening the country through bio-economy. In the future, China will focus on developing emerging vaccines, small molecule drugs, emerging Chinese medicines, high-yield and high-quality crops, biological pesticides, biopharmaceuticals, bioenergy and environmental biotechnology. At the same time, expand the biotechnology industry chain and develop biomaterials.
By 2000, the output value of China's biotechnology industry has reached more than 20 billion yuan, and more than 20 biotechnology parks have been established in Beijing, Shanghai, Guangzhou and Shenzhen. Modern biotechnology involves about 500 enterprises with more than 50,000 employees, including more than 300 pharmaceutical biotechnology enterprises and more than 200 agricultural biotechnology enterprises.
By 2006, the annual output value of China's modern biotechnology industry reached 60 billion yuan, and the annual output value of traditional biotechnology industry reached more than 300 billion yuan. In 2007, there were about 500 enterprises involved in modern biotechnology, with an annual output value of nearly one trillion yuan. Development plan of bio-industry: By 20 15, China's bio-industry has formed a distinctive industrial development capability, which has significantly enhanced its contribution to economic and social development and occupied a favorable position in the global industrial competition pattern. By 2020, the biological industry will become the pillar industry of the national economy. Specific objectives include:
The structural layout is more reasonable. The key areas of the bio-industry have achieved all-round development, new formats have grown healthily, key areas have achieved characteristic development and dislocation development, and the industrial structure has been optimized. Cultivate a number of leading enterprises and innovative small and medium-sized enterprises with international competitiveness, and form a number of industrial clusters and advantageous industrial chains with their own characteristics and international influence.
The ability to innovate has been significantly enhanced. An industrial technological innovation system with international advanced level has basically taken shape. The proportion of R&D investment in the sales of major enterprises has increased significantly, and the number of key core technologies to achieve breakthroughs has increased significantly. The number of overseas authorized patents has greatly increased, and a number of innovative products with independent intellectual property rights have been widely used.
The scale and quality have been greatly improved. From 20 13 to 20 15, the average annual growth rate of the output value of the biological industry remained above 20%. By 20 15, the added value of bio-industry will double the proportion of GDP compared with 20 10, and the rate of industrial added value will be greatly improved.
The development environment has improved significantly. Form a relatively perfect management system for market access, price formation and market supervision of new biological products and technologies, establish a two-way incentive policy system for encouraging innovation on the supply side and the demand side, and improve the service systems for industry public services, biosafety guarantee and industrial statistics.
Social benefits have been accelerated. Biotechnology and biological products have been widely used, and the role of bio-industry in improving population health, ensuring food and energy security, promoting green growth, improving ecological environment and increasing employment opportunities has been significantly improved. However, the bio-industry in China is relatively scattered, small in scale and weak in technical force. Therefore, we should make full use of the adjustment means of government and market resource allocation to revitalize China's technology, equipment and facilities and talent stock, so as to effectively integrate the advantages of all aspects.
Biological industry, like other high-tech industries, will become an important engine of China's economic development in the future. However, compared with the potential and demand of rapid industrial development, the lack of funds and financing difficulties have become the bottleneck faced by many biotechnology enterprises. The development of bio-industry urgently needs the intervention of venture capital. Many investors have begun to pay attention to this industry.
Different from the traditional medicine industry, the biotechnology industry felt the severe cold and winter brought by the financial tsunami within one month. The whole biotechnology industry has also experienced the most brutal capital market crash in history. After the baptism of the financial tsunami, the market value of most biotechnology companies will return to nature and investors will be more cautious, which may be a good thing for the industry. This industry has a strong vitality, it is constantly developing new products, it will always maintain its creativity, and it will become more powerful in the tortuous development process.
The average annual growth rate will exceed 20%
The State Council issued the "Development Plan of Bio-industry", which made it clear that by 2020, bio-industry will become a pillar industry of the national economy.
The plan also proposes that the average annual growth rate of the output value of the bio-industry will remain above 20% in the next three years, and the added value of the bio-industry will double the proportion of GDP in 20 15 compared with 20 10, and the bio-pharmaceutical industry will form a group of enterprises with an annual output value exceeding 10 billion yuan.
Biological drugs are the priority of medical insurance.
In the biomedical industry, the innovation ability and product quality management ability of biomedical enterprises will be accelerated in an all-round way in the future, so that the annual growth rate of the output value of the biomedical industry will reach more than 20% from 20 13 to 20 15, and a number of new drugs with independent intellectual property rights will be listed, forming a group of enterprises with an annual output value exceeding10 billion yuan. Biotechnology drugs, chemical drugs and traditional Chinese medicine will be supported.
Among them, biopharmaceuticals, biological vaccines, protein and polypeptide drugs and blood products will be the key areas of support. The Plan clearly optimizes the approval procedures for biopharmaceuticals, formulates relevant policies, and improves the inclusion of biopharmaceuticals in the medical insurance product catalogue. In addition, the country will establish a number of biopharmaceutical industrialization research and development platforms related to major human diseases, such as gene bank, strain bank, cell bank and virus bank, and will build the above-mentioned industrialization demonstration projects of antibody drugs, protein polypeptide drugs and new vaccines in the future.
For generic drugs, the innovation and industrialization of chemical drugs will be accelerated around cardiovascular and cerebrovascular diseases, metabolic diseases, malignant tumors, immune diseases, infectious diseases and neuropsychiatric diseases in the future, in which the research and development of new preparations such as slow release, targeting and long-term effect will be emphasized. In this regard, the country will improve the price formation mechanism of chemical drugs and the drug bidding mechanism in the future, implement the registration and filing management system of pharmaceutical raw materials, and establish the selection guide catalogue of pharmaceutical reference preparations.
In addition, biomedical equipment innovation is also the focus of future support. According to the plan, by 20 15, the annual output value of biomedical engineering industry will reach 400 billion yuan, with emphasis on the development of high-performance medical imaging, radiotherapy, in-vivo examination, in-vitro diagnosis and other medical equipment.
Support sub-industries.
In addition to biomedicine and biomedical equipment, the plan also identifies support measures for the future development of bio-agriculture, bio-manufacturing, bio-energy and bio-environmental protection industries.
In supporting the large-scale development of bio-manufacturing, the plan indicates that it will promote the large-scale development and application of bio-based products, especially non-food bio-alcohols, organic acids and bio-olefins. In the future, the certification system for bio-based products will be established, the market incentive policy for the consumption of bio-based products and the circulation system of agricultural raw materials to the industrial field will be formulated, and green technology products will be subsidized. It is estimated that the scale of bio-manufacturing industry will reach 750 billion yuan by 20 15.
In bio-agriculture, it is estimated that the industrial output value will reach 300 billion yuan by 20 15, especially by supporting enterprises to establish long-term and stable cooperative relations with superior science and education units and cultivating a number of leading enterprises.
In terms of bioenergy and bio-environmental protection, by 20 15, the total annual utilization of bioenergy will exceed 50 million tons of standard coal, and the output value of related industries will reach150 billion yuan, especially in the future, the market access mechanism and price formation mechanism favorable to ethanol gasoline and biodiesel will be established. In the next three years, the annual growth rate of the output value of the bio-environmental protection industry will be above 15%, and by 20 15 years, the output value will reach15 billion yuan, among which various special enzyme preparations and microbial agent products for soil and water remediation will be the key support.